Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.12 and traded as low as $2.10. Nautilus Biotechnology shares last traded at $2.10, with a volume of 4,129,224 shares changing hands.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the stock. Roth Capital assumed coverage on shares of Nautilus Biotechnology in a research note on Tuesday, September 29th. They set a "buy" rating and a $3.50 price objective on the stock. Leerink Partners assumed coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $4.00 price target for the company. Zacks Research raised shares of Nautilus Biotechnology to a "hold" rating in a report on Wednesday, September 30th. Finally, Weiss Ratings upgraded shares of Nautilus Biotechnology from a "sell (e+)" rating to a "sell (d)" rating in a research report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nautilus Biotechnology currently has a consensus rating of "Moderate Buy" and an average price target of $3.83.
View Our Latest Analysis on NAUT
Nautilus Biotechnology Price Performance
The stock's fifty day moving average price is $1.89 and its 200-day moving average price is $2.12. The firm has a market cap of $267.48 million, a price-to-earnings ratio of -4.57 and a beta of 0.66.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. The business had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.21 million. As a group, equities research analysts predict that Nautilus Biotechnology, Inc. will post -0.50 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of NAUT. BlackRock Inc. bought a new position in shares of Nautilus Biotechnology during the 2nd quarter valued at $5,025,000. Susquehanna International Group LLP raised its position in shares of Nautilus Biotechnology by 1,710.9% in the second quarter. Susquehanna International Group LLP now owns 890,949 shares of the company's stock valued at $1,666,000 after purchasing an additional 841,749 shares during the period. Fayez Sarofim & Co bought a new position in shares of Nautilus Biotechnology in the second quarter valued at approximately $84,000. Corient Private Wealth LP acquired a new position in Nautilus Biotechnology during the 2nd quarter worth $308,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Nautilus Biotechnology during the 2nd quarter worth about $91,000. 50.71% of the stock is owned by institutional investors and hedge funds.
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology develops a platform designed to measure and analyze proteins at scale. Its approach combines technologies such as protein engineering, nanotechnology and computational analysis to help researchers study the proteome—the full set of proteins produced by a cell, tissue or organism. The company's platform is intended for applications in biological research and drug development, including investigating how proteins relate to health and disease. Nautilus has described its technology as aiming to provide broad, detailed protein measurements that can support research across a range of biological samples.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.